UK drug regulator approves Alzheimer’s drug but government likely won’t pay for it

A doctor points to PET scan results that are part of a study on Alzheimer’s disease at Georgetown University Hospital, on Tuesday, May 19, 2015, in Washington. Credit: AP Photo/Evan Vucci, File Britain’s drug regulator authorized the Alzheimer’s drug Leqembi on Thursday, saying it’s the first medicine to show some impact in slowing the progression of the neurodegenerative disease. But the U.K. government likely won’t be paying for it after an independent agency separately issued draft guidance concluding that the benefits of Leqembi “cannot be considered good value for the taxpayer.” In addition to the cost of the drug, providing Read More